SEC Form SC 13G/A filed by Rubius Therapeutics Inc. (Amendment)

SEC Form SC 13G/A filed by Rubius Therapeutics Inc. (Amendment)

Recent Analyst Ratings for
$RUBY

$RUBY
Analyst Ratings

$RUBY
Press Releases

$RUBY
Financials

$RUBY
SEC Filings

$RUBY
Large Ownership Changes

Chat with this insight

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Rubius Therapeutics downgraded by Guggenheim

SVB Leerink reiterated coverage on Rubius Therapeutics with a new price target

SVB Leerink reiterated coverage on Rubius Therapeutics with a new price target

Fastest customizable press release news feed in the world

Rubius Therapeutics Announces Process to Explore Strategic Alternatives and Leadership Changes

Alltrna Appoints Caroline Kӧhrer, Ph.D., Vice President, Discovery Platform

Cellarity Announces Close of $121 Million Series C Financing

Live finance-specific insights

Rubius Therapeutics to Announce Second Quarter 2022 Financial Results

Rubius Therapeutics to Announce First Quarter 2022 Financial Results

Rubius Therapeutics Reports Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors Demonstrating Single-Agent Activity and Favorable Tolerability

SEC Form 15-12G filed by Rubius Therapeutics Inc.

Rubius Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

SEC Form 25 filed by Rubius Therapeutics Inc.

This live feed shows all institutional transactions in real time.

2/14/23 1:00:53 PM ET

$RUBY

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $RUBY alert in real time by email

SC 13G/A 1 d439009dsc13ga.htm SC 13G/A SC 13G/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 3)*

Rubius Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

78116T 10 3

(CUSIP Number)

December 31, 2022

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(1)	Includes options to purchase 100,000 shares of Common Stock that are exercisable within 60 days of December 31, 2022.

Item 1(a).

Name of Issuer:

Rubius Therapeutics, Inc. (the “Issuer”)

Item 1(b).

Address of Issuer’s Principal Executive Offices:

399 Binney Street, Suite 300, Cambridge, MA 02139

Item 2(a).

Names of Persons Filing:

The names of the persons filing this report (collectively, the “Reporting Persons”) are:

Flagship VentureLabs IV LLC (“VentureLabs IV”)

Flagship Ventures Fund IV, L.P. (“Flagship IV Fund”)

Flagship Ventures Fund IV-Rx, LP (“Flagship IV-Rx Fund”)

Flagship Ventures Fund IV General Partner LLC (“Flagship IV GP”)

Flagship V VentureLabs Rx Fund, L.P. (“VentureLabs Rx V”)

Flagship Ventures Fund V, L.P. (“Flagship V Fund”)

Flagship Ventures Fund V General Partner LLC (“Flagship V GP”)

Flagship Ventures Opportunities Fund I, L.P. (“Flagship Opportunities I”)

Flagship Ventures Opportunities Fund I General Partner LLC (“Flagship Opportunities GP”)

Noubar B. Afeyan, Ph.D. (“Dr. Afeyan”)

Item 2(b).

Address of Principal Business Office or, if None, Residence:

The address of the principal business office of each of the Reporting Persons is:

c/o Flagship Pioneering Inc.

55 Cambridge Parkway, Suite 800E

Cambridge, Massachusetts 02142

Item 2(c).

Citizenship:


		VentureLabs IV		Delaware
		Flagship IV Fund		Delaware
		Flagship IV-Rx Fund		Delaware
		Flagship IV GP		Delaware
		VentureLabs Rx V		Delaware
		Flagship V Fund		Delaware
		Flagship V GP		Delaware
		Flagship Opportunities I		Delaware
		Flagship Opportunities GP		Delaware
		Dr. Afeyan		United States of America

Item 2(d).

Title of Class of Securities:

Common Stock, $0.001 par value per share (“Common Stock”).

Item 2(e).

CUSIP Number:

78116T 10 3

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

Item 4.

Ownership.

The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported are based on 90,371,532 shares of outstanding Common Stock as of October 31, 2022, as reported in the Issuer’s 10-Q filed on November 9, 2022.

Flagship IV Fund is the manager of VentureLabs IV and, as such, may be deemed to beneficially own the shares held by VentureLabs IV.

Flagship IV GP is the general partner of each of Flagship IV Fund and Flagship IV-Rx Fund, and, as such, may be deemed to beneficially own the shares beneficially owned by Flagship IV Fund and Flagship IV-Rx Fund.

Flagship V GP is the general partner of each of Flagship V Fund and VentureLabs Rx V, and, as such, may be deemed to beneficially own the shares beneficially owned by Flagship V Fund and VentureLabs Rx V.

Flagship Opportunities GP is the general partner of Flagship Opportunities I, and, as such, may be deemed to beneficially own the shares held by Flagship Opportunities I.

Dr. Afeyan is the sole manager of Flagship Fund IV GP, Flagship Fund V GP and Flagship Opportunities GP, and as such, may be deemed to beneficially own the shares beneficially owned by VentureLabs IV, Flagship IV Fund, Flagship IV-Rx Fund, Flagship V Fund, VentureLabs Rx V Fund and Flagship Opportunities I.

Each of the Reporting Persons expressly disclaims beneficial ownership of the shares reported in this Schedule 13G except to the extent of its or his pecuniary interest in such shares.

Item 5.

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

Item 8.

Identification and Classification of Members of the Group.

Not applicable.

Item 9.

Notice of Dissolution of Group.

Not applicable.

Item 10.

Certification.

Not applicable.

SIGNATURE

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.


Date: February 14, 2023

FLAGSHIP VENTURELABS IV LLC

By:		Flagship Ventures Fund IV, L.P. Manager

By:		Flagship Ventures Fund IV General Partner LLC General Partner

By:		/s/ Noubar B. Afeyan, Ph.D.
		Noubar B. Afeyan, Ph.D.
		Manager

FLAGSHIP VENTURES FUND IV, L.P.

By:		Flagship Ventures Fund IV General Partner LLC
		General Partner

By:		/s/ Noubar B. Afeyan, Ph.D.
		Noubar B. Afeyan, Ph.D.
		Manager

FLAGSHIP VENTURES FUND IV-RX, L.P.

By:		Flagship Ventures Fund IV General Partner LLC
		General Partner

By:		/s/ Noubar B. Afeyan, Ph.D.
		Noubar B. Afeyan, Ph.D.
		Manager

FLAGSHIP VENTURES FUND IV GENERAL PARTNER LLC

By:		/s/ Noubar B. Afeyan, Ph.D.
		Noubar B. Afeyan, Ph.D.
		Manager


FLAGSHIP V VENTURLABS RX FUND, L.P.

By:		Flagship Ventures Fund V General Partner LLC
		General Partner

By:		/s/ Noubar B. Afeyan, Ph.D.
		Noubar B. Afeyan, Ph.D.
		Manager

FLAGSHIP VENTURES FUND V, L.P.

By:		Flagship Ventures Fund V General Partner LLC
		General Partner

By:		/s/ Noubar B. Afeyan, Ph.D.
		Noubar B. Afeyan, Ph.D.
		Manager

FLAGSHIP VENTURES FUND V GENERAL PARTNER LLC

By:		/s/ Noubar B. Afeyan, Ph.D.
		Noubar B. Afeyan, Ph.D.
		Manager

FLAGSHIP VENTURES OPPORTUNITIES FUND I, L.P.

By:		Flagship Ventures Opportunities Fund I General Partner LLC
		General Partner

By:		/s/ Noubar B. Afeyan, Ph.D.
		Noubar B. Afeyan, Ph.D.
		Manager

FLAGSHIP VENTURES OPPORTUNITIES FUND I GENERAL PARTNER LLC

By:		/s/ Noubar B. Afeyan, Ph.D.
		Noubar B. Afeyan, Ph.D.
		Manager

/s/ Noubar B. Afeyan, Ph.D.
NOUBAR B. AFEYAN, PH,D.

Get the next $RUBY alert in real time by email

Date	Price Target	Rating	Analyst
9/13/2022		Buy → Neutral	Guggenheim
2/25/2022	$14.00 → $5.00	Market Perform	SVB Leerink
11/9/2021	$20.00 → $14.00	Market Perform	SVB Leerink
10/19/2021	$25.00 → $22.00	Equal-Weight	Morgan Stanley

NAMES OF REPORTING PERSONS

  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

  Flagship VentureLabs IV LLC

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a) ☐ (b) ☒

SEC USE ONLY

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware